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ABSTRACI 
Pathological processes in any organ usually lead to activation of apoptosis of specialized cells and rise of extracellular concentration 
of specific antigens. These events usually take the role of trigger for secondary rise of production of autoantibodies with appro-
priate specificity. These kinds of autoimmune reactions are sanogenic in ~ssence, aiming to augmentation of effectiveness of clea-
rance of affected organs. Much more rarely, the primary rise of autoantibody production (not related to real needs of organism 
and not associated to pre-existing disease of organ or tissue) can be detected. Such situations are pathogenic and may be accom-
panied by dinical consequences. The rates of physiologic. adaptive (secondary) autoimmune reactions to pathogenic 
(primary) autoirmu1e reactions may be evaluated at least as 9 to I. Secondary quantitative changes in autoantibody production 
(specific for any pathology) should be considered as a universal marker for virtually all chronic diseases and may be detected 
months or years before the appearance of dinical signs of disea~ Therefore analysis of quantitative changes in the serum content 
of natural autoantibodies may become an effective instrument for early pre-clinical and even pre-nosologic detection of patholo-
gical processes with diffe et 1t organic location and cellular targeting. Future investigations in this field may result in revision of the 
main paradigm of medicine (DISEASE- TREATMENT). and transition to the new one (prognosis - prevention). 
~regulatory autoantibodies. physiologic autoimmunity, imrnunculus. 
Introduction 
Historically, immunology was formed as a 
branch of applied microbiology, therefore "microbio-
logical" points of view were reproduced for decades 
because generations of specialists in immunology we-
re educated by microbiologists. None the less, let us 
consider a not quite inconceivable situation: let us 
imagine - the founders of immunology were not mi-
crobiologists (Louis Pasteur, Paul Ehrlich and others) 
but physiologists (for example, lvan Pavlow, Waiter 
Cannon and others) (Pie. I), and this field has been 
initially developed in the frame of general physiology. 
In such an alternat ive historical reality, the immune 
system could probably be considered mostly as the 
system responsible for maintenance of molecular 
homeostasis, and terms such as "sense of antigenici-
ty", "immune analyzer", "immune image", "immune 
reflex" (instead of secondary immune response) etc., 
could became quite usual. In this case, the term "im-
munity" could be associated rather not with the ha-
bitual alerted guard, busy with permanent war against 
microbes, but with a much more peaceful image of 
housekeeper, busy with utilization and neutralization 
of factors harmful for homeostasis, mostly endoge-
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Pie. I. Historical founders of immunology a) Louis Pasteur (1822-1895). b) Paul Ehrlich (1854-1915) during experiments. c) /-
van Petrovich Pavlow (1849-19 36) walking in front of the building of Historical Faculty of the St-Petersburg Universtty. 
nous in origin. Indeed, over a century ago, Elia Mech-
nikoff had proposed that the main predestination of 
the immune system is not the "Struggle" against 
Non-Self. During the I Qth International Medical Con-
gress (Berlin, 1896), he had claimed that it would be 
wrong to consider immunity as a gendarme of an or-
ganism. Its participation in a constant struggle Host-
against -Parasite is no more than a particular case of a 
much wider biological predestination of the 1mmune 
system - which 1s dynamic participation in self-main-
tenance, self-reparation, and self-optimization, and 
maintenance of a harmony state under the constant 
pressure of Environment 1• Unfortunately, h1s lone voi-
ce was not heard at that time, and similar ideas were 
revived only recently. For example, Polly Matzinger-2 
in her "danger hypothesis" imply that the immune 
system in the least ''think" about Self/Non-Self dis-
crimination, but securing rather of a whole organism 
homeostasis. Her hypothesis, surmises that the im-
mune system is involved in elimination/blocking not 
"foreigners" but "harmfulness" and provide the gro-
und for explanation of various phenomena, now un-
explained, such as constant presence of abundant 
"normal" microbial flora ("fore1gners"!) 1n each healthy 
organ1sm, or pregnancy (why any healthy women pro-
VIdes development of sem1-allogen1c fetus and d1d not 
destroy rt?), etc. Transfer of accent from a defensive 
role to homeostat1c function of the 1mmune system 
leads to re-evaluation of some habrtual views, touch 
upon, for example, phenomena of physiological au-
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toimmunity and general meaning of natural autoanti-
bodies (auto-Abs). 
Regulatory autoantibodies 
Auto-Abs should be attributed to typical recog-
nizing molecules and we should bear in mind that all 
regulatory processes in organism are based upon spe-
cific intermolecular recognition. By means of produc-
tion of specific auto-Abs to any regulatory molecule 
and rts receptor, the immune system may influence 
upon mechanisms of cellular proliferation, differentia-
firm ::tnti tiyit'\g ;\c wt:)ll ~c:: :\ny othPr gPrv~tlr~lly ~PtPr­
mined events in molecular and cellular levels3. For ex-
ampfe, specific Abs against chromatin receptors of en-
docrine cells penetrates into nuclei of cells in vitro 
and in vivo, and influence upon specific mRNA tran-
scription and production/secretion of hormones'~.S. lt 
was supposed that endogenous inter- and intracellu-
lar molecules-communicators (messengers), their re-
ccptors hand by hand with auto /\b~ of according 
specificity form a complicated supra-molecular sys-
tem which provides co-ordinate realization of genet-
ic programs in different cells4. ldiotype-antiidiotypic 
mechanisms may be the cause for appearance of au-
to-antiidiotypic Abs. their COR region could be ste-
reochemically similar to receptor-binding part of lig-
ands (hormones, neurotransmitters, drugs, etc). Such 
auto-antiidiotypes could, at least partially, reproduce 
the biologic activity of original molecules. Many exper-
imental and clinical data directly indicates the reality of 
these phenomena: Abs with specific activity similar to 
hormones. trophic factors, enzymes, drugs of different 
classes, etc. have been described5•7•9·1 0. Supposedly by 
anti-idiotypic mechanism, the immune system may re-
produce biolog;caJiy active copies OF ANY (!) biologi-
cally active molecule. Is it something like a real em-
bodiment of ancient myth about Panacea (navaKEIO, 
Panakeia - all-healing)? In applying to the immune sys-
tem, the term "Jmmunocea" may be proposed. Could 
unique wideness and effectiveness of IVIG therapy be 
partly related to effects of " lmmunoceae"? 
Clearance function of the immune 
system 
One of the most basic (evolutionary initial) ho-
meostatic function of the immune system is rts invol-
vement in general clearance function8. Immune-medi-
ated clearance seems to be an archetype of the im-
mune system functioning and includes elimination of 
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fickle objects such as viruses, bacteria, fungi, but in the 
first place, this function is directed to utilization of e-
merging products of millions of dying cells every mo-
ment. Many activities of the immune system could be 
derived from this ancient function. 
With the lapse of time Mechnikoff, it is widely ac-
cepted that clearance of products (endogenous and 
exogenous in origin) intended to utilization, is carried 
out by macro phages, but this is only half true. Why so? 
On macrophages' surface, there are TL-receptors 
(bind some typical patterns of molecules of bacterial 
wall) and scavenger-receptors (bind some lipopro-
Luir•o iJOif and nQn :~~If in ;;.n~in) rn. I [<;-.NQ¥Qr, if W"' 
were told about self-molecules with abnormal chan-
ges in their structure, which should be uti(ized. or a-
boul w~Le products of dpoplosis of sclf~cclls w~ 
would face evident obstacles because macrophages 
can not "notice" most of them. Macro phages, as such, 
can not d iscern normal serum albumin from defective 
one, or senescent ~rythrGGyt~ from new one, as well 
(1!) lllU~l uf lllc produru o f upoplo tic cells of liver, 
lungs, kidneys. etc. None the less, this issue - what 
macrophage has to gobble and what it should not be 
touched - has been determined quite effectively with 
using of specialized signatures, "tags", attached to uti-
lized items - namely auto-Abs. Specific auto-Abs 
have been attached to any product which should be 
"gulp down" by macrophages. and first of all to waste 
products of apoptosis 11 . In their turn, macrophages 
bind Abs-Antigen complexes (soluble, as well as, par-
ticulate ones) by means of superficial Fc-receptors 
and take them up efficiently by pinocytosis or endo-
cytosis. Metaphorically speaking, Abs-opsonines exe-
cutes the role of scent mark for "blind" dog (macro-
phage) and help to the last "to recognize'' effectively 
the objects intended to utilization. 
Autoantibodies and physiologic 
autoimmunity 
Nota bene: Production of Abs is regulated (fe-
edback principle) by the quantity of according anti-
gens (processed and available for recognition by im-
munocompetent cells) 12. Increase of discharge of wa-
ste products is a pre-requisite for elevated synthesis 
of specific Abs-signatures, and consequent util ization 
of them by macro phages. Individual intensity of apop-
tosis/replacement of different specialized cells is ro-
ughly the same in any healthy adult. Nearly same lev-
els of production of antigenic waste products is prob-
ably the main reason for nearly same serum levels of 
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very different (in terms of specificity) auto-Abs in 
each healthy individuals, practically independent from 
gender and agel11 . In opposite, pathological changes 
in heart or lungs, kidneys or liver, and other organs 
lead to abnormal rise of "cardiotropic", "pulmotrop-
ic'', ''renotropic'', etc. auto-Abs13, because, practically, 
any disease in its early beginning is accompanied by 
notable rise of apoptosis in certain populations of 
specialized cells and massive release of specific anti-
gens. Excessive emission of apoptotic debris (includ-
ing usually "hidden" intracellular tissue-specific anti-
gens) is able to trigger elevated production of auto-
Abs of according specificrt:yS. This kind of easily dete-
cted secondary autoimmune reaction should be con-
sidered as adaptive in essence because these events 
are directed to restoration of disturbed homeostasis 
by means of intensification of clearance of involved 
organs and activation of reparative processes (many 
auto-Abs do stimulate DNA synthesis, increase mi-
totic rate and other signs of reparation)l8•9•11 • That is 
if the content of "cardiotropic", "hepatotropic", etc., 
auto-Abs in blood serum of investigated person put 
in the normal range - this result w ill indicate that ape-
ptotic rates in heart, liver, etc., did not exceed physi-
ological rates. On the other hand, in case of long-
term rise in synthesis of, for example, "pulmotropic" 
auto-Abs - it may be considered as supposed mark-
er of present or forming pathologic process in the 
lungs, even if there are no evident clinical symptoms 
of lung pathology at investigation. In our practice, we 
confront situations when specific changes (rise) in se-
rum auto-Abs content appear months or even years 
before the first clinical signs of the different somatic 
diseases, not always considered as autoimmune in o-
rigin 14. Thereby, elevation of auto-Abs seems to be 
the earliest sign of incipient development of patholo-
gy. Why so? Probably. it may be related to enormous 
excess of specialized cells in any organ (used for pro-
viding of functional reliability) 1 1• As a result any chro-
nic pathological process by nearly any etiology will 
reach the stage of organ insufficiency only after a pro-
longed silent period - when potential of regeneration 
will be exceeded by long-lasting degenerative events. 
Signs of functional insufficiency (as peculiar biochem-
ical changes and clinical symptoms) will appear at this 
stage. So, biochemical and pathophysiological devia-
tions reflect the appearance of perceptible functional 
organ insufficiency. On the contrary, changes in auto-
Abs content have appeared long before, because 
they are related not to organ functional failure, but 
abnormal activation of apoptotic events. Early pre-di-
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sease changes in any organ may potentially be reve-
aled also by histological investigation of biopsy speci-
mens. However, somebody would hardly use such 
(biopsy and histology) an approach for wide popula-
tion investigations/observations for aims of disease 
prognosis and prevention. 
Based upon our own clinical experience and lit-
erature data 14·1 5 we insist in an overwhelming major-
ity of cases, an abnormal rise of serum content of au-
to-Abs with different antigen specificity is a secondary 
event (reflection), induced by primary damage of tis-
sue/organ. This kind of autoimmune reactions should 
be considered as sanogenic, which is positive in es-
sence. However, autoimmune diseases, related to ab-
normal elevation of auto-Abs production and/or ex-
cessive activation of effector lymphocytes are also a 
reality. How sanogenic (positive) and pathogenic (ne-
gative) autoimmune reactions can be differentiated? lt 
seems that primary autoimmune reactions (that is, the 
ones not conditioned by real needs of organism), in 
most cases, are pathogenic. Besides, in theory, secon-
dary immune activation sometimes may be inadequa-
te in intensity, or incorrectly targeted, or inadequately 
regulated, and in each case the result may be rather 
harmful for organism. These pathogenic situations are 
often named by the generalized term "allergy" 11 . 
From a d idactical point of view, we suppose to 
use the term "autoimmunity", preferably, in relation 
to physiologic autoimmune processes. Adaptive im-
mune reactions (secondary mostly) should be clearly 
distinct from "autoallergic" (primary mostly) patho-
genic immune reactions. We propose to use the term 
"autoaJiergy" for non-conditioned by real needs of or-
ganism abnormal rise of production of many cytokines 
and/or auto-Abs (provoked by viruses, bacteria, 
chemicals or other harmful causes). This term may be 
used not only for the designation of classical allergic 
disorders but also, for typical autoimmune diseases. 
Thus: 
I . Primary pathological changes in any organ u-
sually lead to activation of apoptosis in populations of 
specialized cells and are reflected by secondary (ada-
ptive, compensatory) rise of production and blood 
serum content of auto-Abs with according specificity. 
This reaction of the immune system is sanogenic. 
2. Secondary quantitative changes in auto-Abs 
production may be easily detected for months or 
years before appearance of early clinical signs of dis-
ease, and should be considered as universal mark-
er/sign of nearly any (not only autoimmune/autoaller-
gic) chronic disease, includ1ng those, which (in the 
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view of modem medicine) usually are not character-
ized by immune changes. 
3. Much more rarely, physicians meet with pri-
mary rise of auto-Abs production, mostly induced by 
different external stimuli and does not relate to initial 
damage in organs and tissues. Such situations are pa-
thogenic in essence and may lead to immune-medi-
ated pathological changes (autoallergy, autoallergic 
diseases). This possibility should be taken in mind, 
however, in our own practice, an average frequency 
of adaptive (secondary) and pathogenic (primary) au-
toimmune reactions have not exceeded 95: 5. 
ClinicaJ examples 
Patient B.C (29 y, female). Pregnancy 9-10 wks, 
symptoms of threatening miscarriage, abnormal 
blood coagulation, signs of decrease of placental 
blood flow ( doppler). Leucopenia. Serum level of au-
to-Abs against beta2 -Glycoprotein I is below of pop-
ulation norm (data obtained by manufacturer. Sero-
logic markers of anti-phospholipid syndrome had not 
been revealed. 
Results of multiparametric diagnostic investiga-
tion by fLI-P-Complex Kit ("lmmunculus': Russia); 
obtained data has presented in % from population 
norm: auto-Abs against choriogonadotropin -51% 
from population norm; auto-Abs against dsDNA -31 ; 
auto-Abs against beta2-Giycoprotein I -4% auto-Abs 
against collagen -45%; auto-Abs against Fc-fragment 
of lgG -26%; auto-Abs against insulin -49%; auto-Abs 
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Fig. I. Serum level of outo-Abs against beto2-Giycoprotein I 
in investigated samples below of population norm ( acce-
pted os zero level). 
against thyroglobulin -42%; auto-Abs against SI 00 
protein -35%; auto-Abs against SPR06 -46%; auto-
Abs against ANCA -63%; auto-Abs against T rm03 -
58%; auto-Abs against Kim05 -64%. Average Individ-
ual Immune Reactivity (AIIR) is -45% to population 
normal level (that is prominent immune suppression 
takes place); Level of reactivity related to auto-Abs 
against beta2-G~coprotein I is + 76% compare to 
AIIR. Conclusion prominent serologic markers of an-
ti-phospholipid syndrome had been revealed by using 
multiparametric kits for analysis of individual profile 
(or pattern) of serum immune reactivity, but not with 
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Fig. 2. Serologic markers of anti-phospholipid syndrome had been revealed in the same sample by using mulriparomecric kits 
(£U-P-Complex Method) (or onafysis 'Which is based upon individual profrle of serum immune reactivity compare eo individual 
overage level of immune reoaivity (accepted os zero leveQ, but not with monoparometric kit based upon comparison of 
patient serum reaction with "population norm data". 
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monoparametric kits for single antibody level evalua-
tion in comparison with "population nom( (Fig. I , 2). 
Catamnestic clinical observat ions: Miscarriage 
occurred at 12-13 weeks of pregnancy, most proba-
bly in relation to anti-phospholipid syndrome and pla-
cental blood flow disturbances. 
Patient M.N. ( 48 y, male); complains for indefi -
nite weakness and indisposition; 4 episodes of abnor-
mal elevation of blood pressure (up to I 60/ I 00) we-
re noted during the last 4-5 months. 
Results of multiparametric diagnostic investiga-
tion by ELl- Viscera-Test-24 Kit ("lmmunculus': Rus-
sia) in %from population norm (Fig. 3, 4): auto-Abs 
against dsDNA + I% from population norm; auto-
Abs against beta2-Giycoprotein I + 12%; auto-Abs a-
80,0 
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gainst Fc-fragment of lgG +5%; auto-Abs against he-
art antigen beta2-adrenoreceptor -9%; auto-Abs aga-
inst heart antigen Com -3%; auto-Abs against platelets 
antigen T rm -3%; auto-Abs against small vessel antigen 
ANCA -5%; auto-Abs against kidney antigen Kim 
+ 38%; auto-Abs against kidney antigen Kis + 25%; au-
to-Abs against lung antigen Lus -8%; auto-Abs against 
lung antigen Lum -8%; auto-Abs against stomach wall 
antigen Gam -14%; auto-Abs against intestine wall an-
tigen ltm + 7%; auto-Abs against liver antigen HMMP 
-3%; auto-Abs against liver antigen Hes -8%; auto-Abs 
against insulin - I I ; auto-Abs against insulin receptors -
9; auto-Abs against TSH receptors -8; auto-Abs aga-
inst thyroglobulin -1 4%; auto-Abs against adrenal anti-
gen Adr-QC -12; auto-Abs against prostate/spermal 
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Fig. 4. EU-Viscero-Test data 6 months later, after treatment 
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Fig. 5. ELJ-Viscero-Test data of patient with very early stage ofprostatic gland cancer. 
antigen SPR + 18; auto-Abs against SI 00 protein -6%; 
Abs against astrocyte's protein GFAP - I I%; Abs a-
gainst myelin protein MBP + 3%. Average Individual 
Immune Reactivity (AIIR) is - I% to population normal 
level (normal level of general immune reactivity); Pro-
minently elevated immune reactivity against kidney 
cells, and against prostate antigen were found (Fig. 3, 
4). Additional investigation of urine revealed a mod-
erate bacteriuria and pyouria Antibacterial treatment 
was effective and bacteriuria/leucocyteuria disap-
peared. Arterial blood pressure also became normal 
(during I 8 months of regular observation no episo-
des of abnormal elevation of blood pressure were 
noted). Conclusion: Early stage of arterial hyperten-
sion of kidney origin was revealed; treatment of kid-
ney inflammatory process was effective and resulted 
also in successful control of early stage of chronic ar-
terial hypertension of renal origin. 
Patient B.R. ( 64 y.o., male); considered himself a 
healthy person (without any complains). 
Results of muftiparametric diagnostic investigation 
by EU-Viscero-Test-24 K;t ("lmmuncu/us': Russia) in% 
from population norm (Fig. 4): auto-Abs against 
dsDNA +46% from population norm; auto-Abs against 
beta2-Giycoprotein I +I%; auto-Abs against Fc-frag-
ment of lgG + IS%; auto-Abs against heart antigen be-
ta2-adrenoreceptor - I I%; auto-Abs aga.inst heart anti-
gen Corn -8%; auto-Abs against platelets antigen T rm -
7%; auto-Abs against small vessel antigen ANCA -5%; 
auto-Abs against kidney antigen Kim -8%; auto-Abs 
against kidney antigen Kis - I 3%; auto-Abs against lung 
antigen Lus - I 6%; auto-Abs against lung antigen Lum -
12%; auto-Abs against stomach wall antigen Gam -14%; 
auto-Abs against intestine waJI antigen ltm -I I%; auto-
Abs against liver antigen HMMP -6%; auto-Abs against 
liver antigen Hes -I 2%; auto-Abs against insulin -I I ; au-
to-Abs against insulin receptors -I 0; auto-Abs against 
TSH receptors -3; auto-Abs against thyroglobulin -I%; 
auto-Abs against adrenal antigen Adr-QC -2; auto-Abs 
against prostate/spermal antigen SPR + 28; auto-Abs 
against SI 00 protein+ 36%; Abs against astrocyte's pro-
tein GFAP -6%; Abs against myelin protein MBP -8%. 
Average Individual Immune Reactivity (AIIR) is -2% to 
population normal level (normal level of general im-
mune reactivity); Prominently elevated immune reactiv-
ity against kidney cells, and against prostate antigen 
were found (Fig. 5). Additional investigation of prostat-
ic gland with PET revealed abnormally intensive accu-
mulation of glucose in gland tissue; blood level of 
prostate-specific antigen was at upper norm level; can-
cer in situ (histology investigation of biopsy sample) was 
diagnosed in the prostate gland. Patient was treated 
surgically. Three years later any signs of malignancy 
were absent Conclusion: Very early stage of prostatic 
cancer was revealed; treatment was effective. 
Concluding remarks 
Precision multi-parametric investigations of ab-
normal changes in content of plurality of auto-Abs 
may become an effective instrument for early pre-cli-
nical revealing of changes, which can lead to disease, 
with the aim of timely intervention and prevention of 
future disease development Future successes in this 
area may become the ground for revision of the main 
18 
Pie. 2. Founder of the idea of physiological autoimmunity E. E. 
Mechnikoff ( 184 5-1916) and supporter of ideas of preven-
tive medicine L N. T olstoy ( 18 2 8-191 0) during conversa-
tion. 0 1 August 1909, ''Yasnaya Poljana" estate. 
paradigm of modem medicine (DISEASE - TREAT-
MEN1) and transition to the new one (PROGNOSIS 
- PREVENTION). Of course, for transformation of 
the desire into reality not only effective, pre-clinical 
diagnostic methods should be elaborated, but also al-
gorithms of individualized preventive measures ( effe-
ctive and socially realizable) should be proposed and 
accepted by general medical practice. 
Many years ago Leo T olstoy 16 had bitterly writ-
ten: "each individual has own peculiarities, and his 
own new disease, not known to medicine ... Field of 
medicine is practically not investigated. . . All known 
medications may help I I I 000 from expected". Elia 
Mechnicoff was a little more optimistic: ''There are 
no incomprehensible in nature, but a lot of not com-
prehend so far" (Pie 2). 
lmmunophysiology, natural autoimmunity and human health 
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